Similar articles for PMID: 33020231

Year	Number of Results
2008	1
2009	1
2010	1
2011	3
2012	1
2013	6
2014	15
2015	11
2016	18
2017	12
2018	9
2019	17
2020	22
2021	8

1

Poorly differentiated Neuroendocrine carcinoma (small cell) of Parotid Gland and 'Moderately differentiated' Hepatic metastases: a Discordant Histopathology clarified by dual tracer PET-CT (⁶⁸Ga-DOTATATE and ¹⁸F-FDG) for predicting tumor biology and treatment decision-making.

Sharma P, Basu S. Sharma P, et al. J Nucl Med Technol. 2020 Oct 5:jnmt.120.251587. doi: 10.2967/jnmt.120.251587. Online ahead of print. J Nucl Med Technol. 2020. PMID: 33020231

2

MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with ⁶⁸Ga-DOTATATE and ¹⁸F-FDG and Multimodality Anatomic Imaging in Metastatic Neuroendocrine Tumors of Unknown Primary in a PRRT Workup Setting.

Sampathirao N, Basu S. Sampathirao N, et al. J Nucl Med Technol. 2017 Mar;45(1):34-41. doi: 10.2967/jnmt.116.185777. Epub 2017 Feb 2. J Nucl Med Technol. 2017. PMID: 28154019 Free article.

3

Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.

Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, Naik K, Maragkoudakis E, Mohmaduvesh M, Al-Harbi M, Belda M, Caplin ME, Toumpanakis C, Bomanji J. Panagiotidis E, et al. J Nucl Med. 2017 Jan;58(1):91-96. doi: 10.2967/jnumed.116.178095. Epub 2016 Aug 11. J Nucl Med. 2017. PMID: 27516446 Free article.

4

Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.

Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S. Thapa P, et al. Nucl Med Commun. 2016 Oct;37(10):1030-7. doi: 10.1097/MNM.0000000000000547. Nucl Med Commun. 2016. PMID: 27243215

5

Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?

Has Simsek D, Kuyumcu S, Turkmen C, Sanlı Y, Aykan F, Unal S, Adalet I. Has Simsek D, et al. J Nucl Med. 2014 Nov;55(11):1811-7. doi: 10.2967/jnumed.114.142224. Epub 2014 Oct 14. J Nucl Med. 2014. PMID: 25315243 Free article.

6

A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.

Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, Bomanji JB. Kayani I, et al. J Nucl Med. 2009 Dec;50(12):1927-32. doi: 10.2967/jnumed.109.066639. Epub 2009 Nov 12. J Nucl Med. 2009. PMID: 19910422 Free article.

7

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.

Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ. Kayani I, et al. Cancer. 2008 Jun;112(11):2447-55. doi: 10.1002/cncr.23469. Cancer. 2008. PMID: 18383518 Free article.

8

Clinical and Prognostic Value of PET/CT Imaging with Combination of ⁶⁸Ga-DOTATATE and ¹⁸F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms.

Zhang P, Yu J, Li J, Shen L, Li N, Zhu H, Zhai S, Zhang Y, Yang Z, Lu M. Zhang P, et al. Contrast Media Mol Imaging. 2018 Feb 26;2018:2340389. doi: 10.1155/2018/2340389. eCollection 2018. Contrast Media Mol Imaging. 2018. PMID: 29681780 Free PMC article.

9

Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.

Jois B, Asopa R, Basu S. Jois B, et al. Clin Nucl Med. 2014 Jun;39(6):505-10. doi: 10.1097/RLU.0000000000000429. Clin Nucl Med. 2014. PMID: 24662668

10

Prognostic value of a three-scale grading system based on combining molecular imaging with ⁶⁸Ga-DOTATATE and ¹⁸F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias.

Karfis I, Marin G, Levillain H, Drisis S, Muteganya R, Critchi G, Taraji-Schiltz L, Guix CA, Shaza L, Elbachiri M, Mans L, Machiels G, Hendlisz A, Flamen P. Karfis I, et al. Oncotarget. 2020 Feb 11;11(6):589-599. doi: 10.18632/oncotarget.27460. eCollection 2020 Feb 11. Oncotarget. 2020. PMID: 32110279 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed